New Directional Cannula Provides More Flexibility and Control to Balloon Kyphoplasty Procedures

Medtronic plc today announced the U.S. launch of Kyphon Assist™ Directional Cannula for use with its balloon kyphoplasty (BKP) products to treat vertebral compression fractures due to osteoporosis, cancer or benign lesions. This innovative new device allows physicians greater control when inflating the bone tamp while also increasing height restoration capability compared to a traditional balloon kyphoplasty cannula1.

The Kyphon Assist™ Directional Cannula is compatible across the Medtronic portfolio of balloon kyphoplasty products, including the Kyphon Xpander™ II Inflatable Bone Tamps. It provides the following benefits1:

  • Allows for directional control of Inflatable Bone Tamps during a balloon kyphoplasty procedure
  • Additional height restoration in a vertebral body
  • Ability to inflate away from lateral wall and endplate defects
  • Can be exchanged with existing access tools when needed

“Kyphon Assist allows me to directionally inflate my balloon tamp and decide the force and direction of pressure,” said Dr. Thomas G. Andreshak, orthopedic surgeon at St Luke’s Hospital in Maumee, Ohio. “This allows me to obtain the best reduction of the endplates, attempt to maximize height restoration, correction of kyphosis with caution while protecting the lateral, anterior, and posterior walls of the vertebral body.”

Vertebral compression fractures (VCFs) are the most common osteoporotic fractures affecting 1.4 million people worldwide.2 According to the National Osteoporosis Foundation, about 54 million Americans have osteoporosis or low bone mass that puts them at increased risk for a fracture. Breaking a bone is a serious complication of osteoporosis, especially with older patients. Osteoporotic bone breaks are most likely to occur in the hip, spine or wrist.3

A recent study of patients with osteoporotic VCFs treated with a directional balloon technique(n=49) versus traditional nondirectional balloon technique(n=51) reported significantly early and immediate outcome improvement in Visual Analog Scale (VAS), Oswestry Disability Index (ODI) and Roland Morris Disability Questionnaire (RMDQ) scores versus the nondirectional technique at 3 days.4 The study also reported immediate and sustained kyphotic angle correction post-surgery. A lower procedure-related extravasation rate was seen with the directional balloon group as 4 of 49 subjects (8.2%) having bone cement leakage versus 12 of 51 subjects (23.5%), p-value 0.036 with the traditional nondirectional balloon technique.4

“We are excited to offer a new option when it comes to treating osteoporotic patients that allow flexibility and more control with our existing balloon kyphoplasty products,” said Anu Codaty, vice president and general manager of the Interventional Therapies business, which is part of the Restorative Therapies Group at Medtronic. “We are committed to continuously innovating in the vertebral augmentation space. Kyphon Assist will expand the capabilities of our existing Inflatable Bone Tamp Technology and empower physicians in their pursuit of delivering the best clinical solutions to their patients.”

Faced with COVID-19 and recommended treatment and state guidelines related to elective procedures, we encourage clinicians to continue working with their national and local health departments for guidance applicable to their practice to help them make an informed treatment decision on what is appropriate and applicable to their state.


References

  • Medtronic Data on File. 2020.
  •  Boonen S, et al. J Bone Miner Res. 2011;26(7):1627-1637.
  •  National Osteoporosis Foundation Website. www.nof.org
  •  Utilization of the directional balloon technique to improve the effectiveness of percutaneous kyphoplasty. Pu Wang, MD, Jin Li, MD, Zukun Song, MD, Zhan Peng, MD, Guangye Wang, MD, PhD. Medicine (Baltimore). 2019 May; 98(19): e15272

 

SourceMedtronic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version